Yan Li

发表

Discovery of JND3229 as a New EGFRC797S Mutant Inhibitor with In Vivo Monodrug Efficacy.

Yi Chen, Jian Ding, C. Yun, 2018, ACS medicinal chemistry letters.

Identification of compound D2923 as a novel anti-tumor agent targeting CSF1R

Yi Chen, Jian Ding, Lin-jiang Tong, 2018, Acta Pharmacologica Sinica.

7α,8α-Epoxynagilactones and their glucosides from the twigs of Podocarpus nagi: Isolation, structures, and cytotoxic activities.

Sheng Yao, Jian Ding, Lin-jiang Tong, 2018, Fitoterapia.

Discovery of HCD3514 as a potent EGFR inhibitor against C797S mutation in vitro and in vivo

K. Yu, Yi Chen, Jian Ding, 2023, Journal of Cancer.

LS‐106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo

Kai Yu, Yi Chen, Jian Ding, 2021, Cancer science.

YL143, a novel mutant selective irreversible EGFR inhibitor, overcomes EGFRL858R, T790M‐mutant resistance in vitro and in vivo

Xiaoyun Lu, Zheng-chao Tu, Liyan Song, 2018, Cancer medicine.

Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance

Yi Chen, Jian Ding, Lin-jiang Tong, 2020, Molecular Cancer.

Identification of compound D2923 as a novel anti-tumor agent targeting CSF1R

Yi Chen, Jian Ding, Lin-jiang Tong, 2018, Acta Pharmacologica Sinica.

Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance

Yi Chen, Jian Ding, Lin-jiang Tong, 2020, Molecular Cancer.

Discovery and structure - activity relationship exploration of pyrazolo[1,5-a]pyrimidine derivatives as potent FLT3-ITD inhibitors.

Huibin Zhang, Jinpei Zhou, Jian Ding, 2021, Bioorganic & medicinal chemistry.

Preclinical and early clinical studies of a novel compound SYHA1813 that efficiently crosses the blood–brain barrier and exhibits potent activity against glioblastoma

Lin-jiang Tong, Hua Xie, Yan-yan Shen, 2023, Acta pharmaceutica Sinica. B.

ASK120067 (limertinib) exerts pre-clinical anti-tumor activity by inhibiting EGFR exon20 insertion

Yi Chen, Jian Ding, Lin-jiang Tong, 2022, Frontiers in Drug Discovery.

Branched-chain amino acid transaminase 1 confers EGFR-TKI resistance through epigenetic glycolytic activation

Lin-jiang Tong, Huancheng Zhou, Gang Bai, 2024, Signal transduction and targeted therapy.

Discovery of a novel BTK inhibitor S-016 and identification of a new strategy for the treatment of lymphomas including BTK inhibitor-resistant lymphomas.

Lin-jiang Tong, Tao Zhang, Yan Li, 2024, Acta pharmacologica Sinica.